Psychedelic-Focused Manufacturers

Cortexa is a Melbourne-based psychedelic-medicines supplier, formed as a 50/50 joint venture between PharmAla Biotech and Vitura Health. It was the first company in the world to supply psilocybin under Australia's TGA Authorised Prescriber Scheme (2024) and is positioned as the only Australian company able to supply both GMP MDMA and psilocybin for clinical trials and prescriptions under the country's regulated prescribing pathways.

Eywa Biotech is a Uruguayan synthetic-biology company, founded in Montevideo in 2022 by Paola Rodríguez Camarot and Victoria Costa Paz, that uses metabolic engineering and fermentation to produce GMP-grade psychedelic active pharmaceutical ingredients, including psilocybin, DMT, 5-MeO-DMT and bufotenin. It aims to provide a sustainable, high-purity supply chain for psychedelic compounds used in research and therapeutics, and raised a US$2.5 million round led by Tim Draper.

Filament Health is a Canadian natural-psychedelics drug-development company and a leading supplier of pharmaceutical-grade botanical psilocybin. Its patented lead candidate, PEX010, is a standardised natural psilocybin drug candidate used across more than 80 academic and clinical studies worldwide, including Germany's compassionate-use programme and numerous depression, PTSD and cancer-distress trials. On 30 April 2026, Filament was acquired by and became a wholly-owned subsidiary of Red Light Holland (Cboe CA: TRIP), which now advances the PEX010 supply business and a patent portfolio of 76 issued patents across 15 families. In July 2026 Filament agreed to supply PEX010 for an ARQ National Psychotrauma Centre veterans-PTSD study in the Netherlands.

Natural MedTech Pty Ltd is an Australian manufacturer of active pharmaceutical ingredients, founded in 2021, that uses biosynthesis (precision fermentation) to produce psychedelic APIs. It is the only manufacturer of psilocybin and MDMA APIs in Australia, holding Schedule 8 and Schedule 9 cGMP manufacturing licences and complying with TGO 112 and TGO 113. Natural MedTech supplies both API and finished dose forms, has supported more than ten Phase 2 or later clinical trials in Australia and internationally, and runs a sustainable process that avoids petrochemicals, harsh solvents and plastic waste. Supply is via authorised professional and clinical-trial channels only.

Canadian GMP-certified manufacturer of pharmaceutical-grade psilocybin and MDMA, licensed by Health Canada. Optimi's facility in Princeton, British Columbia is one of the largest legal psilocybin production operations in North America. Supplies clinical trial material to researchers in Australia, Israel, and Canada.

PharmAla Biotech (CSE: MDMA) is a Canadian biotech specialising in MDXX-class molecule R&D and GMP MDMA manufacturing. Founded in January 2021 by CEO Nick Kadysh, the company operates two business lines: (1) LaNeo — clinical-grade GMP MDMA supplied to research institutions worldwide under a supply-for-data model, now with a US distribution hub and agreements spanning Mt. Sinai, Yale, UAB, University of Washington, and institutions in Norway and Netherlands; and (2) proprietary drug development led by ALA-002, a patented non-racemic MDMA (70–80% R-MDMA / 20–30% S-MDMA) targeting social anxiety in autism, plus APA-001, a novel non-scheduled MDXX molecule discovered via University of Windsor AI collaboration. ALA-002 holds US Patent No. 12,053,452 (composition of matter, issued 2024), MHRA written guidance that no further preclinical data is needed, and FDA NCE classification. Phase 2a clinical trial drug substance manufacture was contracted with a UK CDMO in December 2025 in preparation for an Australian Phase 2a with University of Sydney (Dr. Adam Guastella). Revenue grew 95% in FY2024 to C$1.04M from MDMA product sales. Note: master list originally classified as private, but is publicly listed on CSE.

Psilo Scientific Ltd is a Health Canada-licensed psilocybin producer and wholly-owned subsidiary of Filament Health Corp (NEO: FH), supplying purified botanical psilocybin (PEX010) to clinical trials including the PSYCHED-PAL palliative care microdosing study; it also licensed PEX010 to Cybin for Phase 2 trials in treatment-resistant depression and alcohol use disorder.

PsyLabs is a privately held psychedelic API developer and pharmaceutical manufacturer supplying naturally derived psilocybin, psilocin, ibogaine, mescaline, DMT, and related compounds for legal research, clinical trial, and drug-development markets. It operates a licensed Southern Africa production and extraction platform and has a strategic licensing/equity relationship with Psyence Biomedical (Nasdaq: PBM).

Psygen is a Canadian GMP-certified active pharmaceutical ingredient (API) manufacturer specialising in psychedelic compounds for clinical research. Founded in 2019 and based in Calgary, Alberta, the company produces pharmaceutical-grade psilocybin, LSD, MDMA, DMT, ibogaine, and 5-MeO-DMT under DEA- and Health Canada-compliant conditions, supplying clinical trial sponsors and research institutions. Psygen raised $5.5M to expand its GMP manufacturing capabilities.